Tectonic Therapeutic Announces Participation at Investor Conferences in March
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
TD Cowen 44th Annual Health Care Conference being held in
Boston on March 4 – 6 -
Leerink Partners Global Biopharma Conference being held in
Miami on March 11 – 13
The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.
About Tectonic Therapeutic
Tectonic Therapeutic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting GPCRs to develop novel therapies for patients inadequately served by current treatments. With its proprietary GEODe™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class, where small molecule pharmacology may be intractable. In February 2024, Tectonic entered into a definitive agreement to merge with AVROBIO, Inc. (Nasdaq: AVRO). Tectonic is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227911667/en/
Tectonic Therapeutic Contacts:
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Media:
Karen Sharma
MacDougall
ksharma@macdougall.bio
(781) 235-3060
Source: Tectonic Therapeutic, Inc.